Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 10/20 | 0.53 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4094079 | 1.00 | ALDH1A1 (0.58) | ALDH1A1LMNAMAPTSIRT6HPGD | |
| SCHEMBL4094612 | 0.87 | ALDH1A1 (0.65) | ALDH1A1LMNAMAPTSIRT6HPGD | |
| SCHEMBL4094609 | 0.87 | ALDH1A1 (0.65) | ALDH1A1LMNAMAPTSIRT6HPGD | |
| SCHEMBL4094639 | 0.86 | ALDH1A1 (0.63) | ALDH1A1LMNAMAPTSIRT6HPGD | |
| SCHEMBL4094634 | 0.86 | ALDH1A1 (0.63) | ALDH1A1LMNAMAPTSIRT6HPGD | |
| SCHEMBL14636531 | 0.83 | MAPT (0.58) | ALDH1A1LMNAMAPTKMT2AL3MBTL1 | |
| SCHEMBL29788578 | 0.76 | ALDH1A1 (1.00) | ALDH1A1LMNAMAPTSIRT6HPGD | |
| SCHEMBL6367942 | 0.76 | ALDH1A1 (1.00) | ALDH1A1LMNAMAPTSIRT6HPGD | |
| SCHEMBL12840924 | 0.75 | LMNA (0.77) | ALDH1A1LMNAMAPTSIRT6HPGD | |
| SCHEMBL2205195 | 0.74 | ALDH1A1 (0.97) | ALDH1A1LMNAMAPTSIRT6HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131436-A1 | Pyrimidine Derivatives | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | disclosed |
| US-20090131436-A1 | Pyrimidine Derivatives | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | disclosed |
| EP-1784392-A2 | PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006021454-A2 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131436-A1 | Pyrimidine Derivatives | DPYD, TYMP, TYMS | ALDH1A1 731/4885LMNA 4042/4885MAPT 2244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.